S-ClassAbout S-Class
Z
ZBHAI Stock Diagnostic Report
Zimmer upgraded to Buy from Sell at UBS on growth and innovation
UBS has upgraded its investment rating for Zimmer Biomet from Sell to Buy and significantly raised its target price.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$95.78Reference entry price at analysis time
01
MARKET SNAPSHOT
Key Indicators at a Glance
02
FUNDAMENTALS
Financial & Fundamental Analysis
The initiation of coverage and upgrade to Buy with a target price of $115 by UBS analyst Patrick Wood serves as a financial momentum that restores market confidence in the growth and innovation of the orthopedic product manufacturer.
03
TECHNICAL VIEW
Technical Position & Response Criteria
Based on the real-time stock price of $95.78, the upward momentum in investment sentiment is being reflected; however, due to the lack of specified support/resistance line data, a conservative approach is recommended until further price indicators are confirmed.
04
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
UBS upgraded its investment rating from Sell to Buy and raised the target price to $115.
05
PROOF OF WORK
Analysis Point vs. Subsequent Price Action
INITIAL · At Analysis (2026-07-28)
FINAL · Current/Verified
Renders the actual stored OHLC data directly in your browser.